Fundraising Fox비비드헬스
Seoul, KR · 2 known investors
Find your way into 비비드헬스
Sign up to see every warm intro you have to 비비드헬스
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 비비드헬스 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Bbiyak is a mobile application that helps users manage GLP-1 obesity treatment through tracking weight loss, injection dosages, appetite control, and exercise. The app serves people using weight loss injections (semaglutide, liraglutide, tirzepatide) in South Korea and includes a community forum for sharing experiences and tips.
Also known as Bbiyak · vvdhealth · 비비드헬스 · 삐약
Investors · 2
How we know: the VCSheet dataset · Not right? Tell us
Company profile
researched Aug 2026Bbiyak (삐약), operated under the vvdhealth.com domain, is a South Korean mobile application built specifically for people using GLP-1 receptor agonist obesity treatments such as semaglutide (Wegovy), tirzepatide (Mounjaro) and liraglutide. The app centralizes the routines that these therapies require: logging injection dates and doses, recording body weight and BMI, tracking appetite-control outcomes (meal size, snacks and drinks, alcohol and late-night eating), and noting fasting windows, diet and exercise sessions.
Beyond record-keeping, the product presents analytical and informational views. A weight-loss graph visualizes progress over time, a weight-loss pace check compares a user's rate of loss against literature-based expected rates, and an estimated drug-concentration graph models the amount of medication remaining in the body based on drug half-life, which the company labels a reference estimate that is not a substitute for professional medical advice. Utility features include a directory for finding hospitals and pharmacies that prescribe or dispense the injections, an injection cost calculator that estimates the number of doses and total spend needed to reach a target weight, and a calorie calculator for a target weight-loss zone.
The app also aggregates peer content: an AI feature groups medication reviews from users with similar body profiles (for example, matching height and weight), and a blog and community section provide explanatory material on obesity medications alongside a forum for questions and shared experience. The company positions Bbiyak as the leading domestic diet-injection management app in Korea.
Business model
Consumer mobile application distributed directly to individual users managing GLP-1 obesity treatment, combining self-tracking tools with informational content and a peer community.
Traction
The website displays an aggregate rating of 4.7 out of 5 alongside user reviews, including one from a user reporting roughly nine months of continuous use, and cites active app updates and direct developer-user communication through an open chat channel.
▸Full profile — market position, technology, go-to-market, geography
Market position
Describes itself as the number one diet-injection management app in South Korea for GLP-1 obesity treatments.
Rather than functioning as a general diet-tracking app, the product is scoped to GLP-1 injection therapy, adding dose-cycle reminders, estimated in-body drug concentration modeling, expected-versus-actual loss pace comparison, and body-profile-matched peer reviews.
Technology
Mobile app features include injection and weight logging with reminders, weight-loss and drug-concentration graphs derived from medication half-life estimates, a weight-loss pace comparison against published clinical expectations, calorie and injection-cost calculators, a hospital and pharmacy locator, and an AI function that curates medication reviews from users with similar body measurements.
Go-to-market
Direct-to-consumer distribution of the mobile app, supported by a company blog, community forum and an operator-run open chat room used for user feedback.
Individuals in South Korea who are prescribed or considering GLP-1 obesity injections such as Wegovy (semaglutide), Mounjaro (tirzepatide) and liraglutide, including first-time users seeking guidance.
Geography
Operates in South Korea, with the product and all published content in Korean; headquartered in Seoul.
Compiled by commissioned research from 3 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
▸Research sources · 3
primary sources listed
- Family 비비드헬스 함께하는 비만약 이야기,삐약vvdhealth.com · web
3 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does 비비드헬스 do?
- Korean mobile app Bbiyak helps GLP-1 obesity-drug users track injections, weight, diet and exercise.
- Who are 비비드헬스's investors?
- 비비드헬스's investors include Kakao Ventures, Lotte Ventures.
- Where is 비비드헬스 headquartered?
- 비비드헬스 is headquartered in Seoul, KR.